Navigation Links
Millennium Reports Outstanding Third-Quarter Results Driven by VELCADE(R) (Bortezomib) for Injection Sales
Date:11/1/2007

orning, November 1, 2007. A conference call and accompanying slides will be webcast live at 8:00 a.m. ET and may be accessed by visiting the Investors section of the Company's website at: http://www.millennium.com.

About VELCADE

VELCADE is being co-developed by Millennium Pharmaceuticals, Inc. and Johnson & Johnson Pharmaceutical Research & Development, L.L.C., (JJPRD). Millennium is responsible for commercialization of VELCADE in the U.S., Janssen-Cilag is responsible for commercialization in Europe and the rest of the world. Janssen Pharmaceutical K.K. is responsible for commercialization in Japan. For a limited period of time, Millennium and Ortho Biotech Inc. are co-promoting VELCADE in the U.S. VELCADE is approved in more than 80 countries worldwide.

In the U.S., VELCADE is indicated for the treatment of patients with multiple myeloma who have received at least one prior therapy. VELCADE is indicated for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy. VELCADE is contraindicated in patients with hypersensitivity to bortezomib, boron, or mannitol. VELCADE should be administered under the supervision of a physician experienced in the use of antineoplastic therapy. In the European Union and many other countries worldwide, VELCADE is approved for patients with multiple myeloma after first relapse.

Risks associated with VELCADE therapy include new or worsening peripheral neuropathy, hypotension observed throughout therapy, cardiac and pulmonary disorders, gastrointestinal adverse events, thrombocytopenia, neutropenia and tumor lysis syndrome. Women of childbearing potential should avoid becoming pregnant while being treated with VELCADE. Cases of severe sensory and motor peripheral neuropathy have been reported. The long-term outcome of peripheral neuropathy has not been studied in mantle cell lymphoma. Acute development or exacerbation of c
'/>"/>

SOURCE Millennium Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... -- New interactive learning forums will ... of the medical device industry at the 2013 ... from June 18-20 in Philadelphia ... ) , These all-new MedTech Innovate ... presentations and implementable solutions on the most cutting-edge ...
(Date:5/17/2013)... MIAMI , May 17, 2013  Insero Health, ... medical needs in epilepsy and related neurological disorders, is ... of its lead compound INS001 in patients with drug-resistant ... Drug and Device Trials (AED) Xll meeting by Dr. ... epileptologist and Chairman of Insero,s Scientific Advisory Board.  In ...
(Date:5/17/2013)... May 17, 2013 Rust removal is one ... non-metal home items could be damaged. To help rust contractors ... of its no-scrubbing rust remover it called Rusterizer. ... available with 10% discount. , My Cleaning Products explained that ... them or by staining them. The first one, it ...
(Date:5/16/2013)... ISPE announced today that ... the newly created position of Vice President of ... be responsible for stimulating ISPE’s revenue growth by ... Society’s Member-led and staff-driven business model, initiating integrated ... membership and product marketing. , “Barbara joins ISPE ...
Breaking Biology Technology:MedTech Innovate Seminars: New Interactive Learning Forums at 2013 MD&M East 2Insero Health Reports Positive Data on Phase I Trial of Novel Therapy for Drug-resistant Epilepsy 2Organic-Based Rust Remover Cuts Down Price by 10%, My Cleaning Products Details Mechanics How to Get the Discount 2ISPE Names Barbara A. Myers, CAE, as Vice President of Professional Development 2
... to Present at Rodman & Renshaw,10th Annual Healthcare Conference" ... Ltd nasdaq:ROSG over PR Newswire, we are advised by ... been added,below the first paragraph. Complete, corrected release follows:, ... a,leader in the development of microRNA-based diagnostics, announced today ...
... DENVER, Nov. 6 Corgenix Medical Corporation,(OTC Bulletin ... test kits, will host a conference call on ... discuss the Company,s financial and operating,performance for its ... the,status of the Company,s product development and marketing ...
... Atherotech to add new apoA1 measurement and apoB:apoA1 ratio to its, ... ... heart disease, BIRMINGHAM, Ala., Nov. ... exhibiting its VAP(R),Cholesterol Test in booth No. 2918 at the American ...
Cached Biology Technology:/C O R R E C T I O N -- Rosetta Genomics Ltd/ 2/C O R R E C T I O N -- Rosetta Genomics Ltd/ 3/C O R R E C T I O N -- Rosetta Genomics Ltd/ 4/C O R R E C T I O N -- Rosetta Genomics Ltd/ 5/C O R R E C T I O N -- Rosetta Genomics Ltd/ 6Atherotech to Exhibit VAP(R) Cholesterol Test at American Heart Association Scientific Sessions 2008 2
(Date:5/16/2013)... in neurodegenerative disease also plays a critical role in ... In a study of the common fruit fly, the ... responsible for sleeping and waking on a 24-hour rhythm. ... sleep-wake cycle is disturbed, making waking up on a ... discovery is particularly interesting because mutations in the human ...
(Date:5/16/2013)... 2013 Integrated Biometrics patented LES (Light ... thin film transistor camera introduces Sherlock, a fingerprint ... in the smallest and lightest form factor available ... Mobile ID FAP 45, Certified scanner is highly ... and weight when compared to optical scanners. ...
(Date:5/16/2013)... world are meeting next week in Toronto. The ... latest in research findings about the brain, the ... disorders that affect them., "Canada is a leader ... the best of neuroscience research done here and ... the Canadian Association for Neuroscience. He also reminds ...
Breaking Biology News(10 mins):Gene involved in neurodegeneration keeps clock running 27th Annual Canadian Neuroscience Meeting, Toronto, May 20-24, 2013 2
... of human embryonic stem cell research receives a tremendous ... the potential of adult stem cells for possible therapies. ... cell research isn't fraught with the controversies that surround ... to isolate and then to multiply in a lab ...
... at the University of Washington and their colleagues at other ... lifespan of mice while reducing the impact of the aging ... journal Science on May 5, lends more credence to the ... reactive chemicals, called "free radicals," can be damaging to the ...
... customized nanoparticles that they developed, University at Buffalo scientists ... brains of living mice with an efficiency that is ... no observable toxic effect, according to a paper published ... Sciences. , The paper describes how the UB scientists ...
Cached Biology News:Researchers discover mechanism for multiplying adult stem cells 2Researchers extend mouse lifespan by protecting against free radicals 2Researchers extend mouse lifespan by protecting against free radicals 3Using nanoparticles, in vivo gene therapy activates brain stem cells 2Using nanoparticles, in vivo gene therapy activates brain stem cells 3
... Basically, most ``special`` dye stains are ... few other non-routine) stains are $9.00. ... a paraffin block, staining, coverslipping and ... (for senile plaques) ,Bodian`s Stain ,Copper ...
... Yeast Whole Genome ChIP-on-chip Microarray is ... yeast (S. cerevisiae) DNA binding proteins ... Agilent DNA microarrays. This set delivers ... with greater true binding events and ...
... S. pombe Whole Genome ChIP-on-chip Microarray ... of yeast (S. pombe) DNA binding ... with Agilent DNA microarrays. This set ... data with greater true binding events ...
... This kit is designed for easy transformation ... protocol allows for successful transformation simply by ... reagents with cultured yeast cells. No complicated ... are required. The kit is particularly well ...
Biology Products: